TY - JOUR
T1 - Resistance to targeted therapies
T2 - delving into FLT3 and IDH
AU - Desikan, Sai Prasad
AU - Daver, Naval
AU - DiNardo, Courtney
AU - Kadia, Tapan
AU - Konopleva, Marina
AU - Ravandi, Farhad
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/6
Y1 - 2022/6
N2 - Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.
AB - Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.
UR - http://www.scopus.com/inward/record.url?scp=85131705343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131705343&partnerID=8YFLogxK
U2 - 10.1038/s41408-022-00687-5
DO - 10.1038/s41408-022-00687-5
M3 - Review article
C2 - 35680852
AN - SCOPUS:85131705343
SN - 2044-5385
VL - 12
JO - Blood cancer journal
JF - Blood cancer journal
IS - 6
M1 - 91
ER -